ArticleMolecular therapy. Nucleic acids2022

Targeting TLR9 agonists to secondary lymphoid organs induces potent immune responses against HBV infection.

Irina Ushach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.